Bowen Hosking

ASX Equities | Earnings Breakdowns | Market Reactions

[Bowen Hosking @bowenhosking]

@SniffRocks Fair on the tariff benefit, but sub revenue and paying circles are the more important metrics for the thesis on this one, and they were positive.

I’d still call it a good quarter, albeit with H2 execution risk.

[Bowen Hosking @bowenhosking]

Life360 (360) had a strong Q2, but the call felt a bit meh. FY26 guidance is heavily weighted to H2, yet management offered little quantitative evidence to support the expected MAU reacceleration when pressed on it.

Looking like it’ll open 25% lower, this could become a buying opportunity if H2 delivers, but the call didn't exactly fill me with confidence.

[Bowen Hosking @bowenhosking]

@RonShamgar Was the analyst, assumably at the lack of detail and certainty on where the bullishness for H2 MAU growth comes from.

[Bowen Hosking @bowenhosking]

‘Wow’ says it all.

$LIF (360)

[Bowen Hosking @bowenhosking]

Life360 (360) had a strong Q2, but the call felt a bit meh. FY26 guidance is heavily weighted to H2, yet management offered little quantitative evidence to support the expected MAU reacceleration when pressed on it.

Looking like it’ll open 25% lower, this could become a buying opportunity if H2 delivers, but the call didn't exactly fill me with confidence.

[Bowen Hosking @bowenhosking]

@ryu_tay Valuation is pretty compelling here and core biz is operationally on track. Happy to hold, but geez that call was just bizarre.

[Bowen Hosking @bowenhosking]

@ryu_tay Yep, small position.

[Bowen Hosking @bowenhosking]

@The_scanner_man Hopefully some shorts needing to get covered today!

[Bowen Hosking @bowenhosking]

$CAR FY26: Solid result with FY27 guidance above consensus. Revenue/EBITDA broadly in line, but NPAT +3.6% vs cons.

FY27 midpoint implies ~2% rev, 1% EBITDA and 4% NPAT upside to consensus.

Strong international growth, with pricing and depth penetration. AI continuing to be a tailwind rather than a disruption.

(Held)

[Bowen Hosking @bowenhosking]

@blackswan2023 Probably more linked to the Sezzle after hours move

[Bowen Hosking @bowenhosking]

@ryu_tay First time promoting it - been on a few times, great platform.

[Bowen Hosking @bowenhosking]

Short-term noise, long-term fundamentals. My thoughts on why ResMed's $RMD margin concerns look temporary and why $REA remains one of the ASX's highest-quality compounders.

https://t.co/z1sLIk2cL8

[Bowen Hosking @bowenhosking]

@ali_aimbot 15%p.a compounded EPS growth is pretty strong.

[Bowen Hosking @bowenhosking]

The market came into $REA worried about a housing transaction cliff.

Management just guided to flat to low single-digit listing declines, low double-digit Buy yield growth, and mid single-digit cost growth. That's a very different outlook to the bearish FY18-19 comparison many were using.

Looks supportive of earnings upgrades, with current FY27 consensus (+6.2% revenue, +13% NPAT) looking conservative.

[Bowen Hosking @bowenhosking]

@The_scanner_man Mid single digit cost growth is great for a business growing their top line at low double digits.

[Bowen Hosking @bowenhosking]

@ryu_tay Who knows in this market. They’re ahead of consensus so will get some earnings upgrades and it’s not expensive.

In before it’s down 12% today 😂

[Bowen Hosking @bowenhosking]

@ryu_tay Nice, goodluck us.

[Bowen Hosking @bowenhosking]

@ryu_tay Don’t jinx us Cramer

[Bowen Hosking @bowenhosking]

@Tze_C Imagine Jensen asking customers to stump up $400m in Nvidia equity before they can order GPU’s 😉

[Bowen Hosking @bowenhosking]

Am I the only one that finds the $MGH/Firmus relationship a little strange?

Invest hundreds of millions into Firmus, mark the investment up through earnings, then receive an $855m contract from Firmus.

I’m sure it’s all above board, but there’s a fair bit of circularity here… 🧐